Mass Spectrometry in Peptide QC: Identity, Multiple Charges, and MS/MS

A synthetic peptide leaves the resin as a mixture: the target sequence, deletions (a residue missing), truncations (the chain stopped short), methionine or cysteine oxidations, incomplete Fmoc deprotection byproducts, and residual salts and solvents. Reverse-phase HPLC with UV detection at 214 nm separates that mixture and quantifies each peak, but does not say what each peak is. Two different impurities can co-elute at the same retention time and appear as one. Without mass, '≥98 % purity' is just a number that does not prove identity.

Mass spectrometry (MS) resolves this by measuring the mass-to-charge ratio (m/z) of the peptide ion. If observed mass matches the theoretical mass computed from the sequence, identity is confirmed. If it differs by 1 Da (possible deamidation), 16 (oxidation), 22 (sodium adduct), or 42 (acetylation), the delta itself is a diagnostic. That is why a serious CoA never carries HPLC alone: it carries HPLC plus MS, minimum. For clinically intended peptides, regulators push further toward LC-HRMS with individual impurities identified above a defined threshold.

ESI (electrospray ionization) and MALDI (matrix-assisted laser desorption/ionization) are both soft ionization techniques compatible with peptides. The operational difference for QC matters. ESI ionizes from a solution, typically the eluate of an HPLC column — hence the common LC-ESI-MS setup. The peptide carries multiple basic groups (lysines, arginines, the free N-terminus), so it usually appears as multiply charged species: [M+H]+, [M+2H]²+, [M+3H]³+, and so on. That extends the effective range of the instrument and lets modest m/z analyzers handle large peptides.

MALDI-TOF ionizes from a dry crystalline matrix using a laser pulse. It produces predominantly singly charged ions ([M+H]+), giving spectra that are dramatically simpler to read: one peak, one mass. It is fast, tolerates salts and biological matrix better, and is the classic tool for confirming identity by a molecular fingerprint. The trade-off is weaker quantification and lower sensitivity for complex mixtures. A common QC practice is to use both: LC-ESI-MS to profile impurities through the elution, MALDI-TOF to confirm the intact mass of the final fraction.

Every element has isotopes. Carbon is mostly 12C, but ~1.1 % of atoms are 13C. For a small molecule that is background noise; for a 30–50-residue peptide the most abundant isotopologue is no longer the 'all-12C' one. The spectrum shows an isotopic cluster of peaks ~1 Da apart: the monoisotopic peak (each element at its most abundant isotope) and then M+1, M+2, etc. Monoisotopic mass is the sum using the most abundant isotope of each element. Average mass uses the natural-abundance weighted average.

Up to roughly 1500–1700 Da, a high-resolution instrument (Orbitrap, FT-ICR, modern Q-TOF) resolves every peak in the cluster and the report quotes monoisotopic mass with sub-ppm accuracy. Above that range, cluster peaks merge into an envelope and what gets measured naturally is the average mass. A clean CoA states which of the two it reports, what resolution was used, and what the error is in ppm or Da. 'Observed mass: 5066.7' on its own is a weaker claim than it looks.

For a 1–2 kDa peptide, a reasonable tolerance is ±0.1 Da on high-resolution instruments or ±0.5–1 Da on low-resolution quadrupoles. Anything beyond that deserves an explanation: a post-synthesis modification, an unremoved adduct, or weak calibration.

In ESI the same peptide appears at several m/z depending on how many protons it captured. If the peptide mass is M, expected ions are [M+nH]ⁿ⁺ at m/z = (M + n·1.00728) / n. A fast rule: within one isotopic cluster, the spacing between adjacent peaks is 1/n, so 0.5 Da spacing means charge 2+, 0.33 Da means 3+. That single check prevents mistaking a large multiply charged peptide for a small singly charged one.

Beyond protonation there are adducts. [M+Na]+ sits +22 Da above [M+H]+ and betrays sodium in the solvent or the vial; [M+K]+ is at +38. Common losses: water (-18), ammonia (-17), CO (-28). These are not always contamination — they are source-side artifacts — but a spectrum dominated by sodium adducts typically signals poorly desalted material. Formal reports therefore quote the deconvoluted neutral mass rather than raw m/z, so the reader compares against theoretical without mentally peeling off protons and sodiums.

Two isomeric peptides (same composition, different sequence) share the exact same intact mass. Intact MS cannot tell them apart. That is where MS/MS comes in: a peptide ion is selected, fragmented — usually by CID or HCD (collision-induced dissociation) — and the fragments are analyzed. Standard Roepstorff-Fohlman nomenclature (refined by Biemann) labels ions by where the backbone breaks and which side keeps the charge. Under CID/HCD the most frequent are b ions (charge retained on the N-terminal side) and y ions (charge on the C-terminal side).

Every residue added to the chain adds a specific mass to the corresponding b or y ion. Reading the differences between consecutive peaks in either series reconstructs the sequence residue by residue. For a synthetic peptide of ≤30 residues, reasonable b/y coverage confirms the full sequence. For longer chains or labile modifications (phosphorylations, glycosylations), ETD or EThcD complements with c/z series that preserve those modifications. A research-grade CoA usually does not print the full MS/MS spectrum, but it should at least state 'sequence confirmed by MS/MS' with the fragment coverage reported (for example, '≥85 % of expected b/y ions assigned').

A properly written MS section of a CoA contains, at minimum: technique (ESI-MS, MALDI-TOF, LC-HRMS), theoretical mass (monoisotopic and/or average, stated), observed mass, error (in Da or ppm), observed ions (typically [M+H]+ plus two or three further charge states for ESI), and an identity statement. For lots aimed at in vitro or preclinical studies, an LC-MS chromatogram showing that the main HPLC peak corresponds to the expected mass is the norm.

Red flags to look for as a researcher: 'observed mass' without theoretical mass next to it; no ppm error when high resolution is claimed; high HPLC purity but no MS attached; spectra dominated by [M+Na]+ over [M+H]+; or 'sequence confirmed' claims with no fragment coverage stated. Rule of thumb: if the MS section of the CoA does not let you recompute the match between theoretical and observed on a calculator, the CoA is incomplete. For a peptide used in preclinical work, that level of analytical traceability is not a luxury — it is the floor for experimental results to be interpretable.